Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Greenwald

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cureus|February 12, 2026
Microbiome Differences in Preeclampsia Versus Lupus NephritisHarshita Nadella, Julia L Armstrong, Rachel Greenwald, et al.
Frontiers in Oncology|October 20, 2023
Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinomaCaroline S Jansen, Yujin Choi, Sean T Evans, et al.
World Journal of Urology|January 9, 2025
Development and validation of nomograms and integrated software incorporating preoperative C-reactive protein level for prognostic prediction of nonmetastatic clear cell renal cell carcinoma: Results from the International Marker Consortium for Renal Cancer (INMARC) RegistryWei Chen, Hajime Tanaka, Masaki Kobayashi, et al.
Nature|October 24, 2024
Differentiation fate of a stem-like CD4 T cell controls immunity to cancerMaria A Cardenas, Nataliya Prokhnevska, Ewelina Sobierajska, et al.
Immunity|December 29, 2022
CD8<sup>+</sup> T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumorNataliya Prokhnevska, Maria A Cardenas, Rajesh M Valanparambil, et al.
Journal for Immunotherapy of Cancer|July 21, 2022
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in bloodJennifer Wilkinson Carlisle, Caroline S Jansen, Maria Andrea Cardenas, et al.
Urologic Oncology|June 26, 2024
Predictive factors for recurrence and outcomes in T1a renal cell carcinoma: Analysis of the INMARC (International Marker Consortium for Renal Cancer) databaseFranklin Liu, Luke Wang, Margaret F Meagher, et al.
Research Square|August 16, 2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
Nature Cancer|February 27, 2025
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cureus|February 12, 2026
Microbiome Differences in Preeclampsia Versus Lupus NephritisHarshita Nadella, Julia L Armstrong, Rachel Greenwald, et al.
Frontiers in Oncology|October 20, 2023
Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinomaCaroline S Jansen, Yujin Choi, Sean T Evans, et al.
World Journal of Urology|January 9, 2025
Development and validation of nomograms and integrated software incorporating preoperative C-reactive protein level for prognostic prediction of nonmetastatic clear cell renal cell carcinoma: Results from the International Marker Consortium for Renal Cancer (INMARC) RegistryWei Chen, Hajime Tanaka, Masaki Kobayashi, et al.
Nature|October 24, 2024
Differentiation fate of a stem-like CD4 T cell controls immunity to cancerMaria A Cardenas, Nataliya Prokhnevska, Ewelina Sobierajska, et al.
Immunity|December 29, 2022
CD8<sup>+</sup> T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumorNataliya Prokhnevska, Maria A Cardenas, Rajesh M Valanparambil, et al.
Journal for Immunotherapy of Cancer|July 21, 2022
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in bloodJennifer Wilkinson Carlisle, Caroline S Jansen, Maria Andrea Cardenas, et al.
Urologic Oncology|June 26, 2024
Predictive factors for recurrence and outcomes in T1a renal cell carcinoma: Analysis of the INMARC (International Marker Consortium for Renal Cancer) databaseFranklin Liu, Luke Wang, Margaret F Meagher, et al.
Research Square|August 16, 2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
Nature Cancer|February 27, 2025
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
Pageof 1